High-dose coenzyme Q10 therapy versus placebo in patients with post COVID-19 condition: a randomized, phase 2, crossover trial

Diagnosis and management of post-COVID (Long COVID) in children: a moving target

“…Importantly, many patients or experts are suggesting for nutraceuticals for the treatment of PCC in children [6 ▪ ]. So far, no studies have been published in children, and the most solid trial in adults did not find any differences in outcomes [56,57]. A case series from our team showed improvement of chronic gastrointestinal symptoms in children [39], but we are not having benefits for other systemic symptoms.…”

Studies towards investigation of Naphthoquinone-based scaffold with crystal structure as lead for SARS-CoV-19 management

“…Therefore, the primary step towards antiviral drug designing processes for acquiring a lead candidate is to understand a target molecule's structural and electronic features. In this regard, we were intrigued to explore the scope of a naphthoquinone-based scaffold synthesized by our group as a potential lead for the SARS-CoV-19 management, as naphthoquinones exhibit unique biological properties attributed to the electronic properties that are brought through their structural characteristics and also earn them less toxicity, optimum solubility, and effective target binding [6] . The effectiveness of naphthoquinone warrants investigation also because they bear an uncanny resemblance to quinone-containing drugs.…”

Coenzyme Q10 therapy in patients with post COVID-19 condition

“…We commend Hansen and colleagues 1 for reporting the randomized, double-blind, crossover trial which investigated the use of high-dose coenzyme Q10 (CoQ10) in patients with post COVID-19 condition (PCC). Despite being purported as one of the potential interventions for PCC due to their ability to reverse mitochondrial dysfunction in patients with PCC, 2 the trial 1 reported no significant reduction in the number nor severity of PCC-related symptoms with the use of CoQ10.…”

“…Notably, more than half of the participants included in the randomized trial 1 reported by Hansen et al. were either overweight or obese.…”